Sutro Biopharma

illustration of two arrows going in opposite directions
Biotech

Ipsen hands back Sutro's ROR1 ADC at center of $875M deal

Ipsen has backed out of a $900 million biobucks deal for Sutro Biopharma’s ROR1-directed antibody-drug conjugate.
James Waldron Aug 8, 2025 6:15am
parasail Blue Lagoon parachute

Gilead's accounting chief hits the exit—Chutes & Ladders

Mar 14, 2025 8:30am
A series of dice with a bag on them illustrating cost cuts

Sutro discards CEO, 50% of staff and lead ADC to save cash

Mar 14, 2025 7:05am
image of two race cars neck and neck

Ipsen joins ADC race via $900M biobuck deal with Sutro

Apr 2, 2024 7:26am
parachutes peru

FDA promotes Bumpus to replace Woodcock—Chutes & Ladders

Dec 1, 2023 9:48am
investment money shot vaccine pharma dollar

Blackstone, Sutro ink royalty pact worth up to $390M biobucks

Jun 26, 2023 1:47pm